Navigation Links
Phase 3 Data Show Intravenous Golimumab Inhibited Radiographic Progression in Patients with Active Rheumatoid Arthritis
Date:11/12/2012

itis is a chronic, systemic inflammatory condition that is often characterized by symptoms that include pain, stiffness and inflammation, and in some cases, joint destruction and disability.  It is estimated that 1.5 million Americans[1] and more than 23.5 million people worldwide[2] are affected by the condition, for which there is no cure.

About SIMPONI
SIMPONI is a human monoclonal antibody that targets and neutralizes excess TNF-alpha, a protein that when overproduced in the body due to chronic inflammatory diseases can cause inflammation and damage to bones, cartilage and tissue.  SIMPONI is approved in 57 countries for adult rheumatologic indications, including the United States where SIMPONI received FDA approval in April 2009 for the treatment of moderately to severely active rheumatoid arthritis (RA) with the medicine methotrexate, active psoriatic arthritis alone or with the medicine methotrexate and active ankylosing spondylitis.  SIMPONI is available either through the SmartJect® autoinjector or a prefilled syringe as a subcutaneously administered injection.  For more information about SIMPONI, visit www.SIMPONI.com.  

Applications requesting approval of SIMPONI as a subcutaneously administered anti-TNF-alpha therapy for the treatment of adult patients with moderately to severely active ulcerative colitis have been submitted in Europe and the U.S.

In addition, applications requesting approval of I.V. golimumab for the treatment of adults with moderately to severely active RA have been submitted in the U.S. and Europe.

Janssen Biotech, Inc. discovered and developed SIMPONI and markets t
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. (OTC ... U.S. provisional patent application concerning composition of matter, biological ... targeted tumor cell death.  This patent ... double stranded RNA molecules (VSRNAs) which interfere with the ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
(Date:4/17/2014)... of the most popular vaccine brands for children may ... be overlooking some cost factors when choosing vaccines, driving ... option, according to a new study by University of ... can be driven by numerous factors," says Sheldon H. ... of computer science and of mathematics at the U. ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... April 17, 2014U.S. military personnel who served in ... concussive traumatic brain injury (TBI) were compared to ... other medical reasons. Differences in measures of overall ... months after injury are reported in an article ... journal from Mary Ann Liebert, Inc., publishers. The ...
(Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
(Date:4/17/2014)... (SACRAMENTO, Calif.) An international team led by researchers ... protein complex, which plays a key role in cell ... process. This is the first time the complex has ... could make cyclin B1/Cdk1 an excellent target to control ... medicine. The research was published online today in the ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... recurrence of an employee,s medical leave of absence from work tends ... physical one, a Centre for Addiction and Mental Health (CAMH) study ... from their jobs do not have another disability leave for at ... contrast, most who have had a physical health disability leave have ...
... Reporter , TUESDAY, June 28 (HealthDay News) -- A vaccine ... some promise, while another designed to alter insulin production fails, ... results of both studies were slated to be presented Tuesday ... Type 1 diabetes often appears early in life and ...
... with life,s punches, while for others, every misfortune is a jab ... although most people require significant adversity to become depressed the ... 30 percent of people with first-time depression and 60 percent of ... minor misfortunes. But no one knew why. Now, ...
... , TUESDAY, June 28 (HealthDay News) -- ... to the flu vaccine, which suggests that the drugs ... as previously believed, researchers say. The small study ... were treated with sunitinib and six who were treated ...
... Diego, Calif., has joined a national consortium of research institutions ... library of primary human tumors with the goal of developing ... consortium member, STSI will provide solid human tumor samples to ... study. STSI scientists will then have access to the models ...
... Science University have discovered a naturally occurring disease in monkeys ... a discovery that could have a major impact on efforts ... disease that the researchers discovered in monkeys at OHSU,s Oregon ... that could give significant clues into how multiple sclerosis develops ...
Cached Medicine News:Health News:Workplace mental health disability leave recurs sooner than physical health leave, CAMH study shows 2Health News:Trials of Type 1 Diabetes Vaccines Bring Mixed Results 2Health News:Trials of Type 1 Diabetes Vaccines Bring Mixed Results 3Health News:Sweating the small stuff: Early adversity, prior depression linked to high sensitivity to stress 2Health News:Sweating the small stuff: Early adversity, prior depression linked to high sensitivity to stress 3Health News:Certain Cancer Drugs Don't Interfere With Flu Vaccine: Study 2Health News:Scripps Translational Science Institute joins Jackson Laboratory tumor consortium 2Health News:Researchers at Oregon Health & Science University discover MS-like disease in monkeys 2
All Keeler magnifiers and telescope are available on a clip to fit over the patient's own spectacle...
This set offers the full range of Keeler magnifiers and telescopes....
This set is designed to introduce the low vision practitioner to the Keeler telescopic system....
Significantly more compact and tidier in overall looks yet retain many of the excellent features of the more comprehensive Haag type systems., ,Filters include Cobalt blue; green (red free); neut...
Medicine Products: